Mykofenolatmofetil Actavis (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolatmofetil Actavis, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ‑transplant rejection and to treat selected autoimmune disorders such as lupus nephritis and vasculitis.

GNH USA supplies Mykofenolatmofetil Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mykofenolatmofetil Actavis is used in immunosuppressive regimens for organ transplantation and autoimmune disease management. - Prevention of graft rejection: reduces the risk of acute and chronic rejection after solid‑organ transplantation. - Lupus nephritis: helps control renal inflammation and proteinuria in systemic lupus erythematosus. - ANCA‑associated vasculitis: contributes to disease remission and preservation of organ function.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Upper respiratory infections: increased susceptibility to colds.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count causing fatigue. - Severe infections: opportunistic bacterial, viral or fungal infections. - Hepatotoxicity: elevated liver enzymes or liver injury. - Malignancy risk: potential increased incidence of certain cancers. - Progressive multifocal leukoencephalopathy: rare but serious brain infection.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust dosing in patients with impaired kidney function. - Avoid live vaccines: increased risk of vaccine‑derived infection. - Pregnancy considerations: discuss potential fetal risks with the prescribing physician. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Mykofenolatmofetil Actavis may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression can cause severe cytopenias. - Strong CYP3A4 inhibitors (e.g., ritonavir): increase mycophenolic acid exposure and toxicity. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Warfarin: may alter INR, requiring more frequent monitoring. - Inactivated vaccines: possible reduced immunogenicity, monitor protective titers. - Antacids or sucralfate: may affect absorption of mycophenolic acid, separate administration times.